Amit Prabhakar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amit Prabhakar has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Akiko Hata
Cardiovascular Research Institute, UCSF, San Francisco, California, USA
1 shared publication - Bhushan N. Kharbikar
Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, USA
1 shared publication Brian B. Graham
Lung Biology Cen
1 shared publicationCarlos O. Lizama
Cardiovascular Research Institute, University of California
1 shared publicationCarmen M. Treacy
Department of Medicine, University of Cambridge
1 shared publicationDipti Prasad
Neurobiology Division, Defence Institute of Physiology & Allied Sciences, DRDO, Lucknow Road, Timarpur, Delhi-110054, India
1 shared publication
Latest Publications
- Open Access
Reversal of pulmonary veno-occlusive disease phenotypes by inhibition of the integrated stress response
Pulmonary veno-occlusive disease (PVOD) is a rare form of pulmonary hypertension arising from EIF2AK4 gene mutations or mitomycin C (MMC) administration. The lack of effective PVOD therapies is compounded by a limited understanding of the mechanisms driving the vascular remodeling in PVOD. We show that the administration of MMC in rats mediates the activation of protein kinase R (PKR) and the integrated stress response (ISR), which lead to the release of the endothelial adhesion molecule VE-Cadherin in the complex with Rad51 to the circulation, disruption of endothelial barrier, and vascular remodeling. Pharmacological inhibition of PKR or ISR attenuates the depletion of VE-Cadherin, elevation of vascular permeability, and vascular remodeling instigated by MMC, suggesting potential clinical intervention for PVOD. Finally, the severity of PVOD phenotypes was increased by a heterozygous BMPR2 mutation that truncates the carboxyl tail of BMPR2, underscoring the role of deregulated BMP signal in the development of PVOD.
Open AccessReversal of pulmonary veno-occlusive disease phenotypes by inhibition of the integrated stress response
Pulmonary veno-occlusive disease (PVOD) is a rare form of pulmonary hypertension arising from EIF2AK4 gene mutations or mitomycin C (MMC) administration. The lack of effective PVOD therapies is compounded by a limited understanding of the mechanisms driving the vascular remodeling in PVOD. We show that the administration of MMC in rats mediates the activation of protein kinase R (PKR) and the integrated stress response (ISR), which lead to the release of the endothelial adhesion molecule VE-Cadherin in the complex with Rad51 to the circulation, disruption of endothelial barrier, and vascular remodeling. Pharmacological inhibition of PKR or ISR attenuates the depletion of VE-Cadherin, elevation of vascular permeability, and vascular remodeling instigated by MMC, suggesting potential clinical intervention for PVOD. Finally, the severity of PVOD phenotypes was increased by a heterozygous BMPR2 mutation that truncates the carboxyl tail of BMPR2, underscoring the role of deregulated BMP signal in the development of PVOD.
- Open Access
- 10 January 2015
- Published by Sciencedomain International in British Microbiology Research Journal
- Vol. 8 (6) , 644-654
Ebselen a Seleno-organic Molecule Inhibits Alteration in the Biological Responses in Hypoxic Human Alveolar Lung Epithelial Cells
Ebselen is a lipid-soluble seleno-organic compound whose benefits have been shown in a variety of diseases and in experimental studies including anti-inflammation, anti-proliferation, anti-angiogenesis, anti carcinogenesis and anti-oxidation properties. This study aimed to evaluate the effect of ebselen against hypoxia-induced biological responses in human alveolar epithelial cells (A549 cells). Hypoxia treatment increased the generation of reactive oxygen species, proinflammatory cytokines/chemokines, cell death and proliferation in A549 cells in a time-dependent manner. Notably, Ebselen treatment significantly reduced the production of reactive oxygen species and levels of biochemical markers for lipid peroxidation. Ebselen treatment increased the antioxidant enzyme superoxide dismutase activity as well. This seleno-organic compound also reduced the production of proinflammatory chemokines IL-8 and proinflammatory cytokine TNF-α. It is worth noticing that, Ebselen enhanced the viability as well as proliferation of hypoxic A549 cells. Collectively, these data demonstrate that the Ebselen attenuates the alterations in biological responses in hypoxic human alveolar epithelial cells. Our results further suggest that that ebselen could be used as a potential chemopreventive compound to restore the normal biological response in hypoxic cells and thus inhibiting the progression of the lung carcinoma.
- 10 January 2015
- Published by Sciencedomain International in British Microbiology Research Journal
- Vol. 8 (6) , 644-654
Open AccessEbselen a Seleno-organic Molecule Inhibits Alteration in the Biological Responses in Hypoxic Human Alveolar Lung Epithelial Cells
Ebselen is a lipid-soluble seleno-organic compound whose benefits have been shown in a variety of diseases and in experimental studies including anti-inflammation, anti-proliferation, anti-angiogenesis, anti carcinogenesis and anti-oxidation properties. This study aimed to evaluate the effect of ebselen against hypoxia-induced biological responses in human alveolar epithelial cells (A549 cells). Hypoxia treatment increased the generation of reactive oxygen species, proinflammatory cytokines/chemokines, cell death and proliferation in A549 cells in a time-dependent manner. Notably, Ebselen treatment significantly reduced the production of reactive oxygen species and levels of biochemical markers for lipid peroxidation. Ebselen treatment increased the antioxidant enzyme superoxide dismutase activity as well. This seleno-organic compound also reduced the production of proinflammatory chemokines IL-8 and proinflammatory cytokine TNF-α. It is worth noticing that, Ebselen enhanced the viability as well as proliferation of hypoxic A549 cells. Collectively, these data demonstrate that the Ebselen attenuates the alterations in biological responses in hypoxic human alveolar epithelial cells. Our results further suggest that that ebselen could be used as a potential chemopreventive compound to restore the normal biological response in hypoxic cells and thus inhibiting the progression of the lung carcinoma.